Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs

Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs

Autoimmune phenomena are frequently observed in patients with chronic lymphocytic leukemia (CLL) and are mainly attributable to underlying dysfunctions of the immune system. Autoimmune cytopenias (AIC) affect 4−7% of patients with CLL and mainly consist of autoimmune hemolytic anemia and i...

Full description

Bibliographic Details
Main Authors:	Candida Vitale, Maria Chiara Montalbano, Chiara Salvetti, Elia Boccellato, Valentina Griggio, Mario Boccadoro, Marta Coscia
Format:	Article
Language:	English
Published:	MDPI AG 2020-01-01
Series:	Cancers
Subjects:	chronic lymphocytic leukemia autoimmune hemolytic anemia immune thrombocytopenia ibrutinib idelalisib venetoclax
Online Access:	https://www.mdpi.com/2072-6694/12/2/282

Similar Items

Prognosis and new therapeutic approaches in chronic lymphocytic leukemia treatment
by: Otašević Vladimir, et al.
Published: (2019-01-01)

Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence
by: Monia Marchetti, et al.
Published: (2022-04-01)

The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia
by: Alessandro Noto, et al.
Published: (2021-05-01)

Possibilities of therapy recurrent b-cell chronic lymphocytic leukemia associated with autoimmune complications: data from literature and personal observation
by: S. R. Goryacheva, et al.
Published: (2018-07-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Isacco Ferrarini, et al.
Published: (2022-04-01)

Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
by: Valentina Griggio, et al.
Published: (2020-11-01)

Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
by: Francesco Angotzi, et al.
Published: (2022-02-01)

Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella Analysis
by: Monia Marchetti, et al.
Published: (2022-03-01)

Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia
by: Claudia Tandler, et al.
Published: (2020-09-01)

Autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia
by: Samer Al Hadidi, et al.
Published: (2020-06-01)

Iron Overload in Patients with Chronic Lymphocytic Leukemia Complicated by Autoimmune Hemolytic Anemia: A Case Report
by: Mohammad Ali, et al.
Published: (2020-03-01)

Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment
by: A. V. Rudakova, et al.
Published: (2020-04-01)

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
by: Elizabeth M. Muhowski, et al.
Published: (2022-11-01)

Autoimmune Complications in Hematologic Neoplasms
by: Wilma Barcellini, et al.
Published: (2021-03-01)

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
by: T. E. Byalik
Published: (2018-07-01)

Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis
by: Stephanos Vassilopoulos, et al.
Published: (2022-09-01)

Revisiting Autoimmunity in Chronic Lymphocytic Leukemia: Prognostic Value of Positive Direct Antiglobulin Test in a Retrospective Study and Literature Review
by: Ahmed SA, et al.
Published: (2021-04-01)

Successful Management of Ibrutinib-Induced Thrombocytopenia in a Patient with Chronic Lymphocytic Leukemia: No Interruption, Only Reduction
by: Simge Erdem, et al.
Published: (2024-03-01)

Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia
by: Candida Vitale, et al.
Published: (2021-07-01)

Danazol in Refractory Autoimmune Hemolytic Anemia or Immune Thrombocytopenia: A Case Series Report and Literature Review
by: Hsu-En Huang, et al.
Published: (2022-11-01)

Pharmacists’ Role in Managing Patients with Chronic Lymphocytic Leukemia
by: Kevin Y. Chen, et al.
Published: (2020-03-01)

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
by: Francesca Romana Mauro, et al.
Published: (2021-06-01)

Difficulties of anemia diagnosis in patients with B-cell chronic lymphocytic leukemia
by: I. S. Piskunova, et al.
Published: (2021-06-01)

Unbalanced immune system: immunodeficiencies and autoimmunity
by: Giuliana Giardino, et al.
Published: (2016-10-01)

Epidemiological profile, clinical, paraclinical, and evolutionary of adult autoimmune cytopenia cases in East of Algeria
by: Aziez Chettoum, et al.
Published: (2021-01-01)

PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives
by: Iwona Hus, et al.
Published: (2022-03-01)

Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia
by: Ayşe Kaya, et al.
Published: (2024-03-01)

Hashimoto′s thyroiditis associated Evans syndrome: A rare case report on the clustered autoimmune disease triad
by: Kalyan Koti, et al.
Published: (2013-01-01)

Prospective analysis of efficacy and safety of BR regime in the first-line treatment of chronic lymphocytic leukemia
by: E A Stadnik, et al.
Published: (2016-12-01)

Rituximab en leucemia linfocítica crónica en recaída y anemia hemolítica autoinmune. Presentación de un caso Use of Rituximab in recurrent chronic lymphocytic leukemia and autoimmune hemolytic anemia. A case presentation
by: Lissete M. Izquierdo Cano, et al.
Published: (2010-08-01)

Management of atypical chronic lymphocytic leukemia presenting with extreme leukocytosis
by: Ramya Muddasani, et al.
Published: (2020-05-01)

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
by: Madanat YF, et al.
Published: (2016-03-01)

Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre‐ibrutinib era: Incidence and risk factors
by: Peter Georgantopoulos, et al.
Published: (2019-05-01)

EXPERIENCE WITH IBRUTINIB IN PATIENTS WITH REFRACTORY AND RECURRENT B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
by: T. V. SOROKINA, et al.
Published: (2017-06-01)

Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?
by: Lukáš Smolej, et al.
Published: (2021-06-01)

Autoimmune Hemolytic Anemia
by: Şinasi Özsoylu
Published: (2012-08-01)

Development of New Drugs for Autoimmune Hemolytic Anemia
by: Zhengrui Xiao, et al.
Published: (2022-05-01)

Evans Syndrome: A case report
by: F. Porcaro, et al.
Published: (2014-08-01)

Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia
by: Sergey V. Nedogoda, et al.
Published: (2021-12-01)

Diagnostic dilemma in Evans syndrome
by: Harish Chandra, et al.
Published: (2015-01-01)